View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 22, 2022

Perspectum’s LiverMultiScan is shown to be cost-effective option for AIH

In the study, the use of the tool demonstrated significant cost savings of up to $381,764 for 100 AIH patients over five years.

Perspectum has announced that its non-invasive liver health diagnostic tool, LiverMultiScan, has been shown in a study to be a cost-effective alternative to liver biopsies for monitoring autoimmune hepatitis (AIH) patients.

Carried out by the Oxford Academic Health Science Network (AHSN) of the National Health Service (NHS) England, the health economic study estimated significant cost savings of up to $381,764 (£336,926) for 100 AIH patients over five years when surveillance liver biopsies were replaced by LiverMultiScan.

The findings from the study suggest that using LiverMultiScan in the clinical care of AIH patients could also improve patient safety and experience, as well as clinical decision-making.

The research into AIH and other autoimmune liver diseases at Perspectum is spearheaded by clinical scientist Dr Elizabeth Shumbayawonda.

Shumbayawonda said: “Although necessary for diagnosis, liver biopsy is not sustainable for long-term monitoring of patients with AIH.

“Factoring in LiverMultiScan’s economic benefits shown in this independent study with its ability to positively impact clinical management by detecting sub-clinical disease and predicting clinical outcomes, along with feedback from all stakeholders involved in patient care, I can say LiverMultiScan is probably one of the best monitoring tools to support the management of patients with AIH.”

LiverMultiScan has been designed to address a critical unmet requirement for non-invasive methods to diagnose and monitor patients with chronic liver diseases, including nonalcoholic steatohepatitis, AIH or viral hepatitis.

Using an artificial intelligence (AI)-enhanced multiparametric magnetic resonance imaging (MRI) scan, LiverMultiScan evaluates the signs of liver disease by simultaneously measuring fat, iron content, and disease activity and severity.

This provides a complete picture of the patient’s liver health.

The company noted that AIH patients need lifelong treatment with corticosteroids and immunosuppressants.

They need close and constant monitoring, currently through the use of liver biopsies, to adjust the dosage of these drugs.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network